Merck & Co., Inc. (MRK) — closed signal from September 20, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 19, 2025.
Predicted vs. what happened
What happened
Reached its target in 53 days.
The thesis — published September 20, 2025
Merck looks like a steady, bounce-back idea with a clear near-term spark: the FDA cleared a faster, shot-based version of Keytruda, which can speed patient visits and help clinics treat more people. Sentiment is positive, and the price looks pushed down, so a recovery over the next 1-3 months is reasonable. The dependable dividend helps cushion dips while we track policy headlines and rivals in cancer drugs in the meantime.
Primary drivers
- Keytruda now has an FDA-cleared quick injection, speeding patient visits
- Price looks beaten down, making a near-term rebound more likely
- Reliable dividend offers income and can soften pullbacks during swings
- Market appetite for strong healthcare names remains constructive
How it played out
MRK: target reached in 53 days
Lyra published MRK at 80.82 on 2025-09-20 with a short-term thesis for 13% growth. The thesis pointed to an FDA-cleared quick injection version of Keytruda, a beaten-down price, a reliable dividend, and constructive appetite for strong healthcare names. The target was 90.55.
Inside the window, MRK reached that target in 53 days. The stock peaked at 104.94 on 2025-11-25, with a 29.8% peak gain, and ended the window at 101.09. The published thesis played out. The price did more than the target required, and it stayed above the target at the end.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.